Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

dopamine/cancro

Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 19 risultati

Somatostatin-dopamine chimeric analogs

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use. Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and

Somatostatin-dopamine chimeric analogs

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use. Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and

Somatostatin-dopamine chimeric analogs

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other

Somatostatin-dopamine chimeric analogs

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other

Somatostatin-dopamine chimeric analogs

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other

Pancreatic cancer therapy and diagnosis

Solo gli utenti registrati possono tradurre articoli
Entra registrati
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/EP2015/058380 filed 17 Apr. 2015, which claims priority to European Patent Application No. 14165053.1 filed 17 Apr. 2014. The entire contents of

Method and compositions for treating tumors having high tyrosinase activity

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and saccharide enzyme activity. The invention is further directed to methods and compositions for treating tumors having high tyrosinase

Method and compositions for treating tumors having high tyrosinase activity

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and .beta.-glucuronidase activity. The invention is further directed to methods and compositions for treating tumors having high

Combination therapy for the treatment of cancer

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE DISCLOSURE The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent. BACKGROUND OF THE DISCLOSURE Increasing evidence suggests

Combination therapy for the treatment of cancer

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE DISCLOSURE The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent. BACKGROUND OF THE DISCLOSURE Increasing evidence suggests

Unifying mechanism and methods to prevent cancer and neurodegenerative diseases

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION Cancer is a disease that begins with mutation of critical genes: oncogenes and tumor suppressor genes. Mutation of critical genes allows for a cancer cell to evolve and ultimately results in pathogenic replication (a loss of normal regulatory control leading to excessive

Methods for identifying and validating selective anti-cancer stem cell agents

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE DISCLOSURE The disclosure relates to methods for the prognosis or treatment of cancer and screening methods and particularly to methods for the prognosis or treatment of cancer that target dopamine receptors and screening methods for the identification and validation of agents that

Imipridones for gliomas

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery

Imipridones for gliomas

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery

Thiazole derivatives

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge